20. November 2009 00:08
Eating disorders (ED) patients display a high prevalence of gastrointestinal symptoms and functional gastrointestinal disorders such as irritable bowel syndrome. These symptoms may interfere with their nutritional management. Ingestion of fructose-sorbitol (F-S) is an established means of gastrointestinal symptom provocation in irritable bowel syndrome patients.
[More]
3f53efe2-3173-4ddf-9f90-996e6bea8688|0|.0
Posted in: Medical Condition News
Tags: Anorexia, Anorexia Nervosa, Cancer, Colorectal Cancer, Diet, Esophageal Cancer, Gastroenterology, Hepatology, Hospital, Irritable Bowel Syndrome, Liver Cancer
19. November 2009 00:22
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
[More]
9f19f465-9b09-4558-8717-5dc5f9c0f5b8|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Anorexia, Biopsy, Biotechnology, Cancer, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diarrhea, Erlotinib, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Pfizer, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting
18. November 2009 10:31
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
[More]
a61a65ac-e150-48dc-bb4d-d91e79fc3c1c|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cancer, Cell, Constipation, Cough, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Peripheral Neuropathy, Pneumonia, Thrombocytopenia, Ubiquitin, Vomiting
3. November 2009 03:02
Schering-Plough Corporation today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
[More]
1a7fbbff-144f-40e7-b2ff-2a96b6917170|1|5.0
Posted in: Drug Trial News | Disease/Infection News
Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hepatology, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Liver Cancer, Lupus, Nausea, Neuropathy, Neutropenia, Pancreatitis, Peginterferon alfa, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Ritonavir, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Virus, Vomiting, Weight Loss
31. October 2009 04:01
Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
[More]
7a84b2da-d9c0-4b12-ab33-9a1c7a2e2f36|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Allergy, Anorexia, Anxiety, Bipolar Disorder, Blood Pressure, CDC, Depression, Glaucoma, Headache, Insomnia, Nausea, Psychiatry, Psychosis, Stroke, Vomiting
31. October 2009 03:09
Schering-Plough Corp. announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
[More]
c3fa1d4f-06bd-4b30-80ad-b27272ea5cd9|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Lupus, Melanoma, Nausea, Neuropathy, Neutropenia, Oncology, Pancreatitis, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Vomiting, Weight Loss
24. October 2009 02:31
Research and Markets (http://www.researchandmarkets.com/research/f59b99/the_wileyblackwel) has announced the addition of John Wiley and Sons Ltd's new report "The Wiley-Blackwell Handbook of Family Psychology" to their offering.
[More]
23. October 2009 05:18
Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.
[More]
b3869b12-d0ac-43e6-9ddd-a0b924411cc7|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Abdominal Pain, Anorexia, Arteriosclerosis, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, CDC, Depression, Drug Abuse, Glaucoma, Hypersensitivity, Hyperthyroidism, Insomnia, Pharmacology, Psychiatry, Psychosis, Stroke
22. October 2009 01:40
Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.
[More]
f4f541c0-5bc7-444a-abff-37b6118c369f|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cell, Constipation, Cough, Cyclophosphamide, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Pneumonia, Rituximab, Thrombocytopenia, Vincristine, Vomiting
19. October 2009 08:38
Schering-Plough today announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.
[More]
5a662e81-818c-4eef-9ba6-1ed80bf43082|0|.0
Posted in: Drug Trial News | Disease/Infection News
Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cholesterol, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Lipoprotein, Liver Cancer, Lupus, Nausea, Neuropathy, Neutropenia, Pancreatitis, Peginterferon alfa, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Transplant, Urticaria, Vasculitis, Virus, Vomiting, Weight Loss
15. October 2009 07:52
Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).
[More]
e238801d-f2fd-4cb0-9da5-261aee505813|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anorexia, Asthma, Beclomethasone, Biotechnology, Bone, Bone Marrow, Cancer, Cell, Corticosteroid, Diarrhea, Drug Delivery, Endometriosis, Nausea, New Drug Application, Oncology, Prostate Cancer, Rhinitis, Stem Cell, Transplant, Vaccine, Vomiting
13. October 2009 01:56
VitalRemedyMD, a physician-established company, offers scientifically formulated integrative nutritional supplements designed to improve the quality of traditional healthcare. "We are proud that VitalProteinRx is now an integral part of Fresenius' armamentarium in helping patients with chronic kidney disease," stated Dr. Seth Baum, Founder of VitalRemedyMD.
[More]
6. October 2009 02:15
Schering-Plough Corp. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.
[More]
2c85957a-8af0-43ed-8612-5a44c9ace7bf|1|4.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hematology, Hepatitis C, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Lupus, Melanoma, Nausea, Neuropathy, Neutropenia, Oncology, Pancreatitis, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Sarcoidosis, Sepsis, Skin Cancer, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Vomiting, Weight Loss
29. September 2009 07:16
The Mental Illness Awareness Week is coming up, from October 4 to 10. On this occasion, Joseph Rochford, Ph.D., Director of the Academic Affairs at the Douglas Mental Health University Institute, presents his top ten list of myths about mental illness.
[More]
22. September 2009 03:40
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
[More]
e0e64c66-1162-4883-9493-87bbe369c5c4|0|.0
Posted in: Drug Trial News
Tags: Alopecia, Anorexia, Apoptosis, Biomarker, Cancer, Cell, Constipation, Diabetes, Diarrhea, Hospital, Kinase Inhibitor, Nausea, Oncology, Renal Cell Carcinoma, Vomiting
Subscribe